Human monoclonal antibodies against amyloid-beta from healthy adults
- PMID: 15708434
- DOI: 10.1016/j.neurobiolaging.2004.06.008
Human monoclonal antibodies against amyloid-beta from healthy adults
Abstract
Two anti-amyloid-beta human antibody-producing cell lines were established from amyloid-beta (Abeta)-selected lymphocytes from peripheral blood of healthy adults. ELISA and Western blot analysis showed that the monoclonal antibodies bound with high affinity to the 43 amino acid-long amyloid-beta peptide. The antigen epitope of these antibodies encountered within amino acids 1-16 of the amyloid-beta peptide. The antibodies did not bind to several immunoglobulin light chain amyloids (AL) and amylin. One of the monoclonals was tested by immunohistochemistry for the binding to frozen sections of brains derived from patients with Alzheimer's disease. It specifically and intensively stained diffuse and core amyloid-beta plaques; whereas, sections from normal brains were not stained. Concomitant staining with a commercial mouse anti-amyloid-beta monoclonal antibody co-localized with that of the human antibody. Simultaneous staining with the human antibody and Congo red implied that the antibody binds primarily to an early immature form of beta-amyloid. Human monoclonal antibodies, which resemble physiologically normal non-pathogenic and possibly protective antibodies in healthy adults, might be attractive candidates for immune therapy of Alzheimer's disease.
Similar articles
-
Humoral immune response to fibrillar beta-amyloid peptide.Biochemistry. 2003 Oct 14;42(40):11682-92. doi: 10.1021/bi030100s. Biochemistry. 2003. PMID: 14529278
-
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. doi: 10.1073/pnas.0436286100. Epub 2003 Feb 3. Proc Natl Acad Sci U S A. 2003. PMID: 12566568 Free PMC article.
-
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.Ann Neurol. 2005 Sep;58(3):430-5. doi: 10.1002/ana.20592. Ann Neurol. 2005. PMID: 16130106
-
Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.Autoimmun Rev. 2006 Jan;5(1):33-9. doi: 10.1016/j.autrev.2005.06.007. Epub 2005 Aug 1. Autoimmun Rev. 2006. PMID: 16338209 Review.
-
Antibody-mediated immunotherapy for Alzheimer's disease.Curr Opin Investig Drugs. 2007 Jul;8(7):519-24. Curr Opin Investig Drugs. 2007. PMID: 17659471 Review.
Cited by
-
Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation.Neurochem Res. 2015 May;40(5):1032-41. doi: 10.1007/s11064-015-1559-4. Epub 2015 Apr 14. Neurochem Res. 2015. PMID: 25868754
-
Strategies for molecular imaging dementia and neurodegenerative diseases.Neuropsychiatr Dis Treat. 2008 Jun;4(3):585-612. doi: 10.2147/ndt.s2154. Neuropsychiatr Dis Treat. 2008. PMID: 18830391 Free PMC article.
-
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.Front Neurosci. 2019 Jan 10;12:1017. doi: 10.3389/fnins.2018.01017. eCollection 2018. Front Neurosci. 2019. PMID: 30686983 Free PMC article. Review.
-
Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice.Hum Vaccin Immunother. 2012 Aug;8(8):1090-8. doi: 10.4161/hv.20472. Epub 2012 Aug 1. Hum Vaccin Immunother. 2012. PMID: 22854673 Free PMC article.
-
MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.J Neurosci. 2013 Apr 17;33(16):7027-37. doi: 10.1523/JNEUROSCI.5924-12.2013. J Neurosci. 2013. PMID: 23595760 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources